Skip to content Skip to footer
Viewpoints_Tahi Ahmadi

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…

Read more

Viewpoints_Jane Chung

Expanding ADC Therapy: Jane Chung from Sutro Biopharma in an Engaging Conversation with PharmaShots

Shots:   Luvelta, an antibody-drug conjugate by Sutro Biopharma is designed to target FRα, expressed in ovarian cancer, developed and manufactured using the company’s proprietary cell-free technology, XpressCF   Today, at PharmaShots, we have Jane Chung, President and CEO at Sutro Biopharma, shedding on the ongoing REFRαME-O1 study evaluating luvelta   Sutro is now enrolling patients for the…

Read more

Insights+ EMA Marketing Authorization of New Drugs in June 2024

Insights+: EMA Marketing Authorization of New Drugs in June 2024

Shots:   The EMA granted Positive Opinion to 4 Biologics and 3 New Chemical Entities in June 2024, leading to treatments for patients and advances in the healthcare industry  The major highlighted drugs were Merck’s Winrevair to treat Pulmonary Arterial Hypertension (PAH) and Roche’s PiaSky for Paroxysmal Nocturnal Haemoglobinuria (PNH)  PharmaShots has compiled a list of 5 drugs that…

Read more

Know Your Investor: Invus (July’24 Edition)

Know Your Investor: Invus (July’24 Edition)

Shots:    Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds   In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices   For a curated report on a specific investor or venture capital, reach out to us…

Read more

Viewpoints_Mina Makar

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …

Read more

PharmaShots Magazine - July 2024 Edition

PharmaShots Magazine – July 2024 Edition

In June, PharmaShots was busy covering the heavy influx of life science updates. Our most-read Top 20 reports covered Nutraceutical and Innovative Digital Therapeutics companies. For the Disease of the Month report, we covered Fabry Disease. The Know Your Investor report featured a condensed report on Google Ventures.  Like every Month, we published reports on Biosimilars, Designations, FDAand EMA approvals.  In August, PharmaShots will…

Read more

ThoughtSpot_Saurabh Chaubey5

4 Biopharma Trends to Watch out in 2024

Shots:  2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation  With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate  The article explores four key…

Read more

CXO Talks: David A. Dodd, Chairman President and CEO of GeoVax Labs Inc. in a riveting conversation with PharmaShots

With great zeal, PharmaShots began an Exclusive Video Interview series for C-suites. An innovative idea to bring thought leaders of the industry, our Exclusive Video Interview offering is a noble initiative by PharmaShots to capture the developments of leading companies. As a part of offering, PharmaShots will be publishing exclusive video interviews every second Monday…

Read more